Integra LifeSciences Holdings Corporation has adopted a new change in control severance program effective January 1, 2026, covering select executives including Executive Vice President and CFO Lea Knight, among others. Under the program, participants are eligible for severance benefits if their employment is terminated without cause or for good reason within two years following a change in control, provided such an event occurs by December 31, 2026. Benefits include a lump sum payment equal to 1.5 times the sum of annual base salary and target cash bonus (2 times for Ms. Knight), a pro rata lump sum of the target bonus for the year of termination, up to 18 months of company-subsidized COBRA premium payments, and up to 12 months of company-paid outplacement services. The program also ensures payment of any outstanding short-term annual cash bonus for prior-year performance. The term of the program expires at the end of 2026 unless extended by the board, and will automatically extend for two years if a change in control occurs.